Table E2.

Echocardiographic and physical parameters of C57BL/6 mice that received clodronate-liposome treatment

	TAC with COP and PBS (n = 8)	TAC with COP and Clodro (n = 8)
Heart rate, beats per minute	483 ± 61	496 ± 84
Anterior wall at end diastole, mm	0.97 ± 0.15	1.13 ± 0.11∗
Anterior wall at end systole, mm	1.34 ± 0.11	1.52 ± 0.14
Posterior wall at end diastole, mm	0.91 ± 0.10	1.12 ± 0.17∗
Posterior wall at end systole, mm	1.20 ± 0.16	1.56 ± 0.34∗
Left ventricular internal diameter at end diastole, mm	4.27 ± 0.31	4.38 ± 0.39
Left ventricular internal diameter at end systole, mm	2.90 ± 0.26	3.11 ± 0.47
Fractional shortening, %	32 ± 3	29 ± 7
Left ventricular end diastolic volume, μL	83 ± 13	91 ± 14
Left ventricular end systolic volume, μL	31 ± 8	38 ± 17
Ejection fraction, %	63 ± 6	59 ± 15
Left ventricular mass, mg	120 ± 14	168 ± 37∗
Cardiac output, mL/min	23 ± 3	26 ± 6
Mitral E/A ratio	1.59 ± 0.28	1.23 ± 0.19∗
Heart weight, mg	162 ± 12	208 ± 15∗
Heart weight/body weight, mg/g	5.9 ± 0.3	6.8 ± 0.3∗
Heart weight/tibia length, mg/mm	9.9 ± 0.63	11.5 ± 0.98∗
Left ventricle weight/body weight, mg/g	4.3 ± 0.4	5.0 ± 0.4∗

Data are presented as mean ± SD. The mice in the TAC with COP and PBS group were subjected to TAC for 6 weeks and subsequent COP for 8 weeks and given PBS during 8 weeks of COP. The animals in the TAC with COP and Clodro group were subjected to TAC for 6 weeks and subsequent COP for 8 weeks and injected with Clodro during 8 weeks of COP. P values were determined using 2-way repeated measures analysis of variance followed by post hoc analysis using the Kruskal–Wallis test for comparisons between 2 groups. TAC, Transverse aortic constriction; COP, cardio-omentopexy; PBS, phosphate-buffered saline; Clodro, clodronate-liposome.

^∗Indicates P < .05 versus TAC with COP and PBS (n = 8 mice per group).